Malignant tumor is one of the main causes of threat to human health at present. Traditional treatment methods for malignant tumors include surgery, radiotherapy and chemotherapy, but none of them can completely kill the tumor cells in the patient’s body, and tumor recurrence and metastasis are still a worldwide problem that plagues tumor treatment. In 2011, the first specific human CTLA4 monoclonal antibody was approved to be marketed for the treatment of malignant melanoma, and the international famous scientific journal “Nature” wrote an article that “the era of tumor immunotherapy has arrived! Immunotherapy has come of age!”. In recent years, autoimmune cell technology has been used to treat melanoma. In recent years, autoimmune cell technology has made rapid development at home and abroad, and is widely used in the comprehensive treatment of clinical tumor patients. It is considered to be the fourth important treatment after surgery, radiotherapy and chemotherapy. One of the most famous treatment cases is the application of DC-CIK technology by Professor Steinman, the 2011 Nobel Laureate in Medicine, to treat his advanced pancreatic cancer, which significantly prolonged his survival for 4 years. Autoimmune cell therapy technology is an important cell therapy technology, which refers to the collection of human peripheral blood mononuclear cells, through in vitro culture, stimulation and activation, so that their number and specific targeting killing function is greatly enhanced, and then returned to the patient’s body, and then specifically kill pathogens, cancer cells, mutated cells and other types of lesions in the body, with the ability to break immune tolerance, activate and enhance the body’s immune capacity It has the dual effects of treatment and health care. Currently, the main therapies include cytokine-induced killer cell (CIK) therapy, dendritic cell (DC) therapy, DC+CIK cell therapy, natural killer cell (NK) therapy and cytotoxic T lymphocyte (CTL) therapy. Cytokine-induced killer cells (CIK) are a heterogeneous population of CD3 and CD56 double-positive cells produced by single nucleated cells stimulated by various cytokines, which combine the powerful anti-tumor activity of T cells with the non-MHC-restricted tumor-killing characteristics of NK cells. By exerting its own cytotoxicity and secreting cytokines to kill tumor cells, the combination of the two ensures an efficient immune system that can significantly inhibit the growth and proliferation of tumor cells and maximize the mobilization of the body’s immune function. Clinical trials have shown the efficacy of DC-CIK cell immunotherapy technology in patients with various immunogenic tumors (including and melanoma, kidney cancer, prostate cancer, lung cancer, bladder cancer, gastric cancer, nasopharyngeal cancer, etc.). A recently published systematic review analyzing 423 patients in 4 randomized controlled trials who received adjuvant percutaneous immunotherapy after hepatectomy for hepatocellular carcinoma showed significantly improved disease-free survival or reduced postoperative recurrence rates (p<0.05) with a high safety profile. Compared with other tumor treatments such as surgery and radiotherapy, autoimmune cell therapy technology is green, safe, and has fewer adverse effects, and the cost is no higher than that of traditional treatments. Generally speaking, cellular immunotherapy is a process of "supporting the righteous and eliminating the evil", which can achieve the purpose of tumor control by improving the patient's own immune function.